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ABSTRACT
As life expectancies rise and the average age of our population increases, there has
emerged a growing need for joint repair and replacement surgeries due to worn out, torn, or
damaged cartilage and bone tissue.

This has resulted in an escalating demand for further

development of the materials used in joint replacement surgeries and advances in joint repair
technology.

Researchers in the tissue engineering and regenerative medicine fields have

furthered the development of advanced materials for musculoskeletal repair by utilizing growth
factors, nanomaterials, and antibiotics within the repair material.
The first aim of this thesis was to provide a summary of the current literature on advances
in joint repair materials. While there have been many advances utilizing calcium phosphates to
aid in bone regeneration; calcium phosphates now just represent a single ingredient within the
state-of-the-art complex biomaterials for joint repair. These combination materials can achieve
up-regulation of osteogenesis within the wound site.

Furthermore, as the advances in

nanofabrication have branched to most fields of science and engineering, the development of
complex nanocomposites has become a common strategy for resolving difficult multi-tissue
repair problems. The development of this class of bioactive, biomaterial nanocomposites is
reviewed within today’s current literature.
The second aim of this thesis was to construct a new biomaterial aiding in joint repair.
By utilizing thermally initiated frontal polymerization, a bioactive, degradable bone augment
was constructed that would provide orthopedic surgeons a material with an extended working
time, good mechanical stability, and potentially osteoconductive and osteoinductive activity.
Four ratios of monomers were explored in an effort to optimize the mechanical properties,
chemical stability and cytocompatibility. The ratio of 5:1 acrylate monomer to thiol monomer

vii

provided the best overall material characteristics:

high cytocompatibility, compressive

mechanical strength of 3.65 MPa, and a maximum propagation temperature of 160°C +/- 10°C.

viii

1. INTRODUCTION
1.1 The Need for Joint Replacements
In the 20th century, medicine and healthcare have evolved to increase the average life
expectancy from about 48 to 79 years of age.[1] While extending the life expectancy of a
population is the goal of healthcare, it has also increased the volume of age-related disorders
found in this increasingly aged population.[2] In the early 1900’s, with a shorter life expectancy,
there was less demand for joint repair or replacement than is found in today’s society.[3] From a
mechanical perspective, the human skeleton contains hundreds of movable and semi-movable
joints, and like any metal joint, the material of the human body can withstand a maximum
compressive and tensile forces which once reached, the bones reach a failure point. As our bone
is loaded and overloaded, microfractures occur regularly. Both microfractures and non-critical
sized fractures of bone undergo a self-healing process to repair the damaged bone.[4] However
over many years of extensive use our joints are prone to damage through bone deformation,
cartilage degradation, and trauma that is effect by the mechanical integrity of bone decreasing
with age.[5] Thus there is a substantial driver for improved techniques in the repair of joint
damage that provides for better outcomes, in terms of costs, surgical success, service life of the
joint repair and patient quality of life. In 2009 alone, there were more than 600,000 total knee
replacement (TKA) surgeries costing about 12 billion dollars.[6] While Schroer et al.’s 20102011 study showed the large range in time to failure of the TKAs, form 10 days to 31 years, the
average time until revision surgery was 5.9 years. Furthermore, they displayed the primary
causes for failure in less than 15 years of ware was aseptic loosening, infection, and instability of
the prosthetic.

After 15 years the next most prominent cause of failure was wear of the

polyethylene spacer.[7]
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1.2 Overview of a Joint Replacement Surgery
The procedure used today empowers the physician to open the joint being replaced (i.e. hip
or knee, etc.), utilize state-of-the-art imaging to map where the head of the joint will be cut, and
implant the femoral and tibia prosthetic components. For ease, this overview of the procedure
will be done using a knee replacement surgery as an example. By using a bone saw and clamps
with set spacing, the femur is shaped to fit a metal prosthetic. Bone cement, a two part
polymerizable formulation, is then mixed and added to the shaped femur.[8] The metal – most
commonly stainless steel, Co-Cr alloys, or Ti alloys[9] – prosthetic is fit, according to size, over
the head of the femur-bone cement layer.

The tibia is then shaped, a hole is drilled

longitudinally down the center of the tibia, and the prosthetic is anchored to the bone head via
this hole.

Figure 1.1 – Post-knee arthroscopy surgery showing layers of bone, bone cement, and prosthetic.

A high-density polyethylene spacer between the prosthetics of the femur and the tibia minimizes
wear on the metal and aids in the movement of the knee.
1.3 Origin of Bone Cement
Replacement joint surgery using polymer anchors, the precedent for today’s procedure,
was first performed in 1962 by Dr. John Charnley who developed the use of an acrylic-based
polymer to anchor an inert stainless steel prosthetic to the patient’s femur.[10] He also was the
2

first to utilize the low friction coefficient of high density polyethylene to decrease wear of the
metal prosthetic while maximizing mobility of the joint post-surgery. His pioneering effort has
led to the extensive use of cemented socket joint replacements and the large market for
commercial use of Bone Cement.[10]
1.4 Literature Overview
Many literature reviews of bone cement have been conducted within the past 25 years. These
overviews have mainly focused on the polymer chemistry, analyzed the mechanical properties,
and drawn comparisons of commercially available bone cements with alternative
compositions.[11-13] Even though, the research to better materials and techniques used in joint
replacement has been relentless, the U.S. Food and Drug Administration regulations and market
forces have retarded evolution of the composition of bone cement over the past 25 years.
Many labs, globally, have done extensive research studying the effects of protein, antibiotic,
and synthetic compound additions to improve the biological activity, decrease the inflammatory
response and infection rate, and aid in repair of fractures.[14-16] Many of these additives utilize
the high surface to volume ratio gained when using nanomaterials. The recent increase in
popularity and advances in nanomaterial and composite fabrication has led to a significant
increase in the bone augment literature on nanocomposites.
The focus of this section is to provide an extensive and through review of the recent advances
pertaining to the effect of additives in Bone Cement and newly developed nanocomposite bone
augments.
1.5 Description of the Need for Bone Augment Fabrication
Currently, bone cement and the standard orthopedic surgical technique place a substantial
time constraint on a physician. Once the physician has prepared the knee for addition of the
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bone cement, he or she is then dependent on the reaction time of the material to continue the
procedure. During polymerization, as the cement transitions from liquid to putty like to a solid
mass, mainly environmental factors (i.e. room temperature) affect the overall time of the
reaction. This makes it difficult for the physician to accelerate or retard the reaction to modify or
correct the physical structure of the cement. Once the two parts of bone cement are mixed it is
difficult for the physician to advance the procedure. The state-of-the-art bone cement materials
tend to be non-degradable and often biologically inert. A preferred advanced bone cement
replacement material would provide a long working time, osteoinductive and conductive
behavior, a degradation rate matched to new bone growth, bone-like mechanical properties and
morphology.
The goal for increased osteogenic properties of a bone construct can be reached through
additives within the mixture.

These additives typically are not involved in the synthetic

mechanism of the construct, but can increase the viscosity and provide additional function.
Additives, or fillers, can be synthetic, biologically derived, or a hybrid of the two. The main
advantage of using synthetic scaffolds and synthetic fillers is the controlled and reproducible
mechanical properties, purity, and bioactivity of the fillers. Despite the benefit of reliability
provided by synthetics, their biological activity is typically limited or inert. Biologically-derived
additives, due to their innate function within in a biological system, enable more potent
biological responses.

Unfortunately, obtaining these tissue types, and proving control and

reliability have been difficult in the past.[17]
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Table 1.1 – A table of the compositions of commercial bone cements [18]:
Cement Type
Palacos® R

Powder Composition
P(MMA/MA) – 84.25 wt.%
+ZrO2 – 15 wt.%
+BPO – 0.75 wt.%
Simplex® P
P(MMA/styrene) – 75 wt.%
+PMMA – 15 wt.%
+BaSO4 – 10 wt.%
+BPO – x
CMW® 1
PMMA – 88.85 wt.%
+BaSO4 – 9.10 wt.%
+BPO – 2.05 wt.%
CMW® 3
PMMA – 88 wt.%
+BaSO4 – 10 wt.%
+BPO – 2.00 wt.%
Endurance
PMMA – 67.05 wt.%
+P(MMA/styrene) – 21.10
wt.%
+BaSO4 – 10 wt.%
+BPO – 1.85 wt.%
Zimmer® dough type
PMMA – 89.25 wt.%
+BaSO4 – 10 wt.%
+BPO – 0.75 wt.%
Osteobond™
copolymer P(MMA/styrene) – 87.5 wt.%
cement
+BaSO4 – 10 wt.%
+BPO – 1.2 – 2.5 wt.%
Sulfix®-60
PMMA – 79.6 wt.%
+P(MMA/BMA) – 8.8 wt.%
+ZrO2 – 9.8 wt.%
+BPO – 0.84 wt.%
Duracem 3
PMMA – 79.7 wt.%
+P(MMA/BMA) – 8.8 wt.%
+ZrO2 – 9.8 wt.%
+BPO – 0.83 wt. %
Boneloc®
P(MMA/BMA) – 90 wt.%
+ZrO2 – 10 wt.%
+BPO – 0.1 wt.%

Monomer Composition
MMA + DMT – 2.0 wt.%
MMA + DMT – 2.6 vol.%

MMA + DMT – 0.816
wt.%
MMA + DMT – 2.487
wt.%
MMA + DMT – 2.00 wt.%

MMA + DMT – 2.75 vol.%
MMA + DMT – 0.75 vol.%
MMA – 84.6 wt.%
+BMA – 14.8 wt.%
+DMPE – 1.7 wt.%
MMA – 83.6 wt%
+BMA – 14.8 wt.%
+DMPE – 1.7 wt.%
MMA – 50 wt.%
+DCMA – 30 wt.%
+IBMA – 20 wt.%
+DMT – 0.5 wt.%
+DHPT – 0.9 wt.%

Key:
Polymers:
PMMA – poly(methyl methacrylate)
P(MMA/MA) – methyl methacrylate/methacrylate copolymer
P(MMA/styrene) – methyl methacrylate/styrene copolymer
P(MMA/BMA) – methyl methacrylate/butyl methacrylate copolymer
5

Initiators:
BPO – benzoyl peroxide
Monomers:
MMA – methyl methacrylate
BMA – butyl methacrylate
DCMA – n-decyl methacrylate
IBMA – isobornyl methacrylate
Accelerators:
DMT – N,N–dimethyl-p-toluidine
DMPE – N,N-dimethyl-amino-phenethanol
DHPT – dihydroxyl-propyl-p-toluidine
Within the medical field, time management is a major concern for both the patient and the
physician. As a patient, increased invasive surgery exposure time can lead to higher infection
rates.[19]

For the physician, a more time efficient surgery can lead to increased surgical

throughput. This has led to the need for time efficient procedures and advanced controllable
materials.
By using thermal frontal polymerization (TFP) the bone augment has an extended life span
before polymerizing than commercially used bone cement and a shorter polymerization time.
This TFP follows a cure-on-demand synthesis of thiol-acrylate monomers based alternative to
the previously described PMMA bone cement. This material’s polymerization is heat activated.
This empowers the physician to fully shape the highly viscous monomer without the time
constraint of the auto-polymerizing MMA. The monomer can be moldable, due to the previously
mentioned hydroxyapatite filler; the viscosity is increased with increasing filler. The chemical
synthesis follows a free-radical chain growth polymerization with a maximum temperature
similar to that of Bone Cement.
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1.6 Overview of Thesis
The first chapter introduces the currently used Bone Cement material, its application in
arthroplastic surgeries, a review of additive enhancements, the need for construction of a bone
augment, and a description of this thesis.
Chapter 2 reviews recent literature for the advances in additives for nano-composites and the
up-regulation of osteogenesis.
Chapter 3 details the in vitro fabrication and analysis of a thiol-acrylate bone augment.
Chapter 4 concludes this thesis and provides direction for future research to better the
development of bone constructs.
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2. STATE-OF-THE-ART BONE CEMENT LITERATURE REVIEW
This literature review extensively examined the most recent advances to the orthopedic
thermoset polymer used in knee arthroplastic surgery, known as bone cement, and has laid a
foundation for the many types of research and recent discoveries targeted toward increasing the
osteogenic properties and/or utilizing nanocomposite materials. Just as the evolution of bone
cement has occurred over the past 40 years, it is still occurring today.

The demand for

consistently strong and increasingly osteogenic and biocompatible scaffolds has driven this body
of research.

While advances have led to new developments, many are not commercially

available, but have potential for use in improved future formulations of bone cement.
The next generation of bone cements has moved toward utilizing ceramics, calcium
phosphates, bioglass, antimicrobials, and nanoparticles to increase the biocompatibility and
bioactivity of the cement. While non-biodegradable augments have been used more historically
for their inert behavior within the body, the next generation of cement development is geared
toward regrowth of tissue using bioactive compounds.

Following this trend bone cement

research is evolving from a development of bioinert to bioactive compounds.

Bioactive

compounds are beneficial in tissue regeneration, however the paradigm is that these compounds
will face regulatory challenges and concern must be given to the fact that growth could lead to
incorrect tissue generation, pain and discomfort for the patient, and costly liability.
The advances discussed and reviewed have furthered the research in increasing the biological
properties of bone cement. This chapter affords a brief summary of the body of literature that
was reviewed along with a discussion of the applicable concepts, models, and literature pertinent
to this project is discussed.
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2.1 Nano-composites

2.1.1 Additive for self-healing
One addition to the current bone cement composition is to add encapsulated, reactive 2octyl cyanoacrylate (OCA), then as micro-fractures occur, the OCA will be released, driving
polymerization and self-healing at the fracture site.[20, 21] With uses of self-healing, the
lifetime of bone cement due to trauma or wear could be greatly extended. The lifespan for the
OCA needs further study since in vivo studies testing the lifespan and reactivity of the OCA as a
self-healing monomer have not been conducted yet. This concept could be further explored as a
fail-safe method for acute fractures to newly installed bone cement.
2.1.2 Bioactive Glass
A recent literature review of the bioactive glass, SiO2 doped with CaO, Na2O, and P2O6,
composites was done by Rahaman et al. and addressed the osteogenic properties of bioactive
glass with calcium phosphate and doped with antibiotics.[22] Bioactive glass has undergone
many formula changes, similar to bone cement, to aid in its’ osteogenic and antimicrobial effects
and this technology holds promise as a potential future osteogenic material. Gao et al.’s review
of bioactive glass displays the recent use of nano-ceramics with biologically derived materials to
form nano-composite materials. In this review it covered a scaffold made of both chitosan and
collagen as a combination or hybrid scaffold with bioglass and showed good biocompatibility
and bone formation when tested in vitro and in vivo, respectively.[23]
As the research in bioactive glass continues, major limitations and challenges for future
studies are balancing the mechanical stability with the degradation rate and tuning the
degradation rate to match tissue ingrowth. As new tissue is regenerated, many formulas of
bioactive glass do not degrade quickly enough resulting in entrapped non-degraded bioglass
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inclusions. The slow rate of degradation leads a release of ions locally and an increase in the pH
that can lead to negative cytotoxic effects.

Also, for international commercialization, no

standard fabrication techniques have been implemented. By using different types of bioglass or
sintering at different temperatures the product can have differing degradation rates and change
the local pH and ionic environment significantly. And lastly, in the many studies conducted
sterilization stability has not been reported, as such, this remains a critical need for commercial
adoption.[24] Once these topics have been addressed, bioactive glass may be advanced into the
clinical trials.
2.1.3 Calcium Phosphate Cements
Wang et al. provides an up-to-date and thorough review of the proliferation ability for a
bone construct out of calcium phosphate. Both the in vitro and in vivo studies reviewed showed
an optimistic outlook for use in conjunction with stem cells to produce bone and vasculature.[25]
To increase the current effects of calcium phosphates and meet the previously seen mechanical
mismatch between bone and the scaffold material a combination of monomers was done.
Macroporous scaffolds of tetracalcium phosphate in combination with alginate microbeads, large
scale, 322 µm diameter, suture fibers and nano fibers electrospun from poly (D,L-lactide-coglycolide) (PLGA), and with rhBMP-2, rhTGF-β1, and VEGF were tested in vivo. This study
showed the mechanical complexity and synergy of the many material types and growth factors
that could be used in bone regeneration. Over 24 weeks, the tetracalcium phosphate scaffold
with microbeads, both large and nano-scale fibers and rhBMP-2 had the best bone ingrowth and
wound healing in a cranial defect model.[26] Many calcium cements utilize hydroxyapatite as
their calcium phosphate agent, however many versions of calcium phosphate have been used.
Other calcium phosphate agents, a monetite/phosphorylate chitosan cement, has been developed
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to address the resorb-ability of the cement.[27] Other examples of calcium phosphates used for
scaffolding are monocalcium phosphate, dicalcium phosphate, β-tricalcium phosphate[28], and
octacalcium phosphate[29] and mixtures with hydroxyapatite, i.e., biphasic calcium phosphate.
Table 2.1 – List of Calcium Phosphate monomers. [30]:
Ca/P ionic
ratio
0.5

Compound

Chemical Formula
Ca(H2PO4)2∙H2O

1.33
1.5
1.5
1.2-2.2

Monocalcium Phosphate Monohydrate
(MCPM)
Monocalcium Phosphate Anhydrous
(MCPA)
Dicalcium Phosphate Dihydrate (DCPA),
mineral monetite
Octacalcium Phosphate (OCP)
α-Tricalcium Phosphate (α-TCP)
β-Tricalcium phosphate (β-TCP)
Amorphous calcium phosphate (ACP)

1.5-1.67

Calcium-deficient hydroxyapatite (CDHA)a

0.5
1.0

1.67
1.67
2.0

Ca(H2PO4)2
CaHPO4
Ca8(HPO4)2(PO4)4∙5H2O
α-Ca3(PO4)2
Β-Ca3(PO4)2
CaxHy(PO4)∙nH2O, n = 3-4.5; 15-20%
H2O
Ca10-x(HPO4)x(PO4)6-x(OH)2-xb (0 <
x < 1)
Ca10(PO4)6(OH)2
Ca10(PO4)6F2
Ca4(PO4)2O

Hydroxyapatite (HA)
Fluorapatite (FA)
Tetracalcium phosphate (TTCP), mineral
hilgenstockite
a
Occasionally, CDHA is named as precipitated HA
b In the case x = 1 ( the boundary condition with Ca/P = 1.5), the chemical formula of
CDHA looks as follows: Ca9(HPO4)(PO4)5(OH)

The ability to tune bone cement’s mechanical strength compared to native bone has been
a topic of interest since the early days of bone graft research. If the mechanical properties of the
scaffold and the native tissue are mismatched, a transfer of the loading could be more on the
bone cement than the bone, lessening the mechanical stimulus on the bone. This commonly
occurs due to error in geometrically positioning the implants on the bone. Unequal static forces
are then loaded creating zones of greater or lesser pressure.[31] This lack of a pressure stimulus
is similar to being in a lesser gravitational setting and will result in adaptation and reshaping the
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native bone to bear less of the load. Ultimately this will lead to bone resorption and potentially
resulting in the failure of the implant.[32] To address this concern, many formulations of bone
cement have been evaluated.
While calcium phosphate-based cement, silane (3-(trimethoxysilyl) propyl methacrylate
(MPS) 1% wt.), has been shown to increase the mechanical strength of the scaffold material.[33]
With addition of mesoporous silica nanoparticles (5% wt.) the compressive mechanical strength
can be increased.[34] The mechanical mismatch in the elastic modulus of the bone and bone
cement can also induce injury or damage to the tissues around the joint. Utilizing linoleic acidmodified bone cement the mechanical properties were better controlled. Linoleic acid addition
adjusted the elastic modulus to a similar strength of cancellous bone.[35] A combination of
linoleic acid and strontium substituted hydroxyapatite was used to decrease the elastic modulus
while maintaining the compressive strength to tune bone cement for vertebroplastic
surgeries.[39] By managing the mechanical properties of a cemented construct and tuning them
to be similar to native bone, bone resorption may be minimized.
2.2 Addition of Bioactive Ions
The next generations of bone cements will seek to increase the biocompatibility and
bioactivity of the augment. By adding ions commonly found in bone such a magnesium or
strontium, the local ionic environment can be modulated resulting in increased osteoconduction
in the surrounding tissue.[36] The signal of strontium release in vivo from a calcium phosphate
based bone cement to bone has shown high biocompatibility and increased osseointegration from
the new bone to the bone cement.[37] The ion influx in the local cellular environment was also
shown to be synergistic with an apatite/poly-lactide composite scaffold in vivo.[38]
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2.3 Addition of Carbon Nanotubes
In order to have a synergistic effect of biocompatibility, high compressive strength, and
good fatigue strength, a combination of the calcium phosphate monomer and carbon nanotubes
have been explored. The PMMA mixture was adjusted by combining hydroxyapatite with
carbon nanotubes or graphene oxide and measured in vitro. The cytocompatibility was similar to
the control sample and osseointegration was observed.[39]

Carbon nanotubes addition to

polystyrene has shown to increase the surface roughness of cast grafts and materials. The
increase in surface roughness has led to an increase in osteoblast cell proliferation and
differentiation.[40] Ormsby et al. have performed one of the few cytocompatibility studies using
multi-walled carbon nanotubes (MWCN) with a –COOH, -NH2, -unfunctionalized with MG-63
osteoblast cells. Cytocompatibility was tested via an MTT assay after 1, 3, and 7 days of cells
seeded on the MWCN-PMMA bone cement. This study showed a significant increase in optical
density of the cells cultured on the MWCN-COOH-PMMA compared to the control, while no
significant difference was shown between the other MWCN-PMMA and the control. Also,
scanning electron microscopy and confocal microscopy displayed similar cellular morphology
for MG-63 cells on the MWCN-PMMA cement and the PMMA cement.[41]
Ormsby et al. increased the fatigue properties and minimized the crack propagation by
testing different concentrations of multi-walled carbon nanotubes (MWCN) in the bone cement
mixture. The end functionality of the MWCN with a carboxyl at 0.1 wt% displayed the highest
cyclic loading properties while the unfunctionalized MWCN displayed the highest
cytocompatibility.[41]
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2.4 Antimicrobial Additives
Infections, which occur in roughly 3.1% of patients in total joint arthroplasties are painful
and difficult to resolve for the patient and costly to treat for the healthcare providers. In an
attempt to address these issues, antimicrobial agents or antibiotics have been used as additives in
the bone cement mixtures.[42] Infection post-primary total knee arthroplasty (TKA) leads to
secondary surgeries and further cost the hospital and patient.
Adjustments have been made by Beyth et al. to the composition of bone cement by
adding nanoparticles with known antimicrobial properties.[43] These ammonium nanoparticles
were bound to the surface of the bone cement to aid in long lasting antimicrobial effects. Other
nanoparticle based antimicrobial effects have been explored using silver nanoparticles. Silver
nanoparticle antimicrobial properties have been extensively published and have gained attention
for applications in the biomedical field.[44] Entrapment of the silver nanoparticles within the
bone cement allows for diffusion of silver ions from the surface of the cement into the solution.
Bone cement integrity was maintained; silver nanoparticles were synthesized and stabilized with
a coating of an organic molecule (tiopronin). The larger nanoparticles (11 nm) showed increased
antimicrobial activity resulting in an increased lag phase of the bacterial growth compared to the
smaller nanoparticles (5 nm).[45] Bioactive glass with silver has also been studied as a delivery
method of silver ions and shown to aid in reducing infection rate.[46] The trade-off with
increased antibacterial compounds is the decrease in mechanical integrity and the difficulty in
controlling the release rate. There is a need for optimization of these aspects.
Commercially-available bone cement that utilizes an antibiotic is not currently available
in the United States.

In Europe, some formulas of bone cement do contain antimicrobial

reagents. Thus far, antimicrobiotic-laden bone cement has been approved by the FDA to be used
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as a secondary application in knee revision surgeries.[47] Hansen et al. addresses the concern
for applying antimicrobial reagents to bone cement is the increasing risk of developing
antimicrobial resistant bacteria. Currently, the FDA has not approved any antimicrobial-cement
combination devices. However physicians are able to combine antibiotics with the bone cement
prior to application.[11] Antibiotics, such as vancomycin, have been used to dope bone cement
and aid in decreasing infection at the site of implantation.[48] Recently, temocillin was added to
a gentamicin-loaded bone cement mixture and tested for drug release and mechanical strength.
Significant doses were eluted within an hour, the antimicrobial activity was maintained, with no
significant difference in mechanical strength of the cement observed.[49]
Unfortunately, it has been reported that the addition of drugs within a calcium phosphate
cement can cause chelation of the calcium, leading to reduced mechanical properties of the
cement.[50] The addition of antibiotics remains a controversial topic as reports of insignificant
differences between patients with and without antibiotic-loaded bone cement have emerged.
Namba et al. followed 22,889 patients post-TKA surgery with 2,030 patients receiving
antibiotic-loaded bone cement. Their results showed no reduction in the number of infections
with antibiotic added cement versus without the antibiotic added.[51]
2.5 Additive to Increase the Biocompatibility
From Arora et al.’s review of PMMA bone cement in 2013, the suggested future work
would be to use bone morphogenic proteins or growth factors to aid in the biocompatibility and
osteogenic properties of bone cement.[52] A list of the growth factors suggested to be delivered
by drug-bone cement combination to aid in bone generation include: growth hormone, bone
morphogenetic protein, transforming growth factor beta, and insulin growth factor.[53]
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Table 2.2 – from Verron et al. describes the function of each growth factor[53]:
Growth Factors
Growth Hormone

Functions
Bone remodeling
Proliferation and differentiation of osteoblasts
Stimulation of osteoclastic resorption activity
Bone
Morphorgenic Proliferation and differentiation of mesenchymal stem cells
Protein
(MSC) and osteoprogenitor cells
Ectopic bone formation
Transforming
Growth Recruitment, proliferation, and diffusion of MSC’s and
Factor – Beta
osteoprogenitor cells
Extracellular matrix production
Angiogenic and inflammation properties
Insulin Growth Factor
Proliferation and migration of MSC and osteoprogenitor cells
New bone formation and mineralization

Another common drug delivered is the bisphosphonate synthetic drug family.
Bisphosphonate is a structural analog of pyrophosphate that inhibits osteoclast activity and upregulates osteogenesis in vitro and in vivo.[54] Bose et al.’s review of bisphosphonates in
ceramic bone cements displays an increase in bisphosphonate containing combination devices in
the literature for bone cements.[55]
To further modify the bone cement formula, originally “0.34 g powder and 173.15 μl
liquid, Endurance MV, DePuy Orthopaedics, Warsaw, IN,”[56] N-acetyl cysteine was use to
terminate radicals after polymerization and aid in increasing the osteoconductivity of the cement.
The modified bone cement formula was able to maintain similar compressive and flexural
strength of the control bone cement. The in vitro results with osteoblast linage cells showed
higher cytocompatibility and the in vivo study displayed better bone-bone cement adhesion.[56]
While maintaining mechanical integrity, addition of phosphorylated 2-hydroxyethylmethacrylate
(HEMA-P) was added to powder portion of the PMMA mixture with calcium salts. With the
HEMA-P cytocompatibility and calcium deposition was increased when tested in vitro.[57]
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When changing the formula of the original bone cement, some physical properties are also
modified. With the addition of transforming growth factor – Beta (TGFβ) to the PMMA recipe, the
porosity and swelling were increased. Pore sizes of about 150 µm to 200 µm were formed. This in vivo
study also showed that a combination of increased porosity and release of TGFβ promoted cell in-growth
and local inflammation was not detected.[58]
Another biomolecule, chitosan, was added to three PMMA polymers each originating from
different sized powder monomers. An in vivo study of the temperature of polymerization and bioactivity
was conducted. The polymer made with the largest sized monomer powder, 50 µm to 150 µm, and with
chitosan showed a decrease in setting temperature from 71.60 ±9.31 °C to 59.04 ±9.59 °C and histology
displayed increased osteoid formation compared to the control sample at 4 weeks.[59, 60] Besides
chitosan, particles containing collagen from cuttlefish have been used as an additive in PMMA bone
cement. The in vivo study showed increased adhesion of the construct to the bone and osseointegration
compared to the PMMA only control.[61]

2.6 Coloration
In application, many physicians use a dye to color the bone cement. This will allow a
physician to more easily identify the bone cement upon revision surgery. A common dye used is
methylene blue, to color the bone cement blue. It has been shown that no mechanical integrity of
the bone cement is lost when methylene blue is added.[62]
2.7 Future Work
From this review many combinations of PMMA bone cement have been reviewed.
Throughout this process of analyzing the gains in biocompatibility of bone cement, more
research has yet to be done to show reliability and consistency in vivo of the bioactive bone
cements. More extensive animal trials, which lead to human trials, will need to be done to
provide the data for use commercially.
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2.8 Conclusion
PMMA bone cement has a significant prevalence in clinical use and has captured
majority of the commercial market of bone cements. Due to the consistency, reliability, and
historical lifetime there has not been a driving need that outweighs the risk for commercialized
bone cement to gain biological activity. As the average person’s lifespan is increased the need
for a longer lasting solution to knee replacement rises. This has led to many additives being
tested to observe if they are able to improve the biological properties of the cement.
These many additions and adjustments to the original bone cement formulation have led
to many breakthroughs in aiding self-healing, improved mechanical strength, improved infection
resistance, and increased in osteogenic up-regulation. The additives reviewed here have led to
bettering the current understanding of bone cement and substitutions of bone cement for joint
arthroplastic procedures. With further research on the consistency of these bioactive materials in
vivo some may become a commercialized product.
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3. IN VITRO EVALUATION OF THERMAL FRONTALLY POLYMERIZED
THIOL-ENE COMPOSITES AS BONE AUGMENTS
3.1 Project Purpose
Due to the large number of total knee replacement (TKR) surgeries conducted per year,
and with projections of increased demand to almost a million primary TKR surgeries per year by
2030 in the United States alone, there is a need to discover more efficient working materials as
alternatives to current bone cements. There is a need for surgeons and hospitals to become more
efficient and better control over the operative environment. One area of inefficiency is the
cement steps during TKR.

Currently the surgeon has very little control over cement

polymerization. This leads to an increase in time, waste, and procedural inefficiencies. There is
a clear need to create an extended working time, moldable, osteoconductive, and osteoinductive
bone augment as a substitution for the current clinically used bone cement where the surgeon has
better control over the polymerization process. This study explored several compositions of
pentaerythritol-co-trimethylolpropane tris-(3-mercaptopropionate) hydroxyapatite composite
materials prepared via benzoyl peroxide-initiated thermal frontal polymerization. The 4:1
acrylate to thiol ratio containing augment material shows promise with a maximal front
temperature of 160 °C +/- 10 °C, with mechanical strength of 3.65 MPa, and 111%
cytocompatibility, relative to the positive control. This frontally-polymerized material may have
application as an augment with controlled polymerization supporting cemented implants.
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3.2 Introduction
During knee replacement surgery, an orthopedic surgeon commonly uses a synthetic
material, poly(methyl methacrylate), referred to as bone cement, to aid in stress distribution and
adhesion of the metal prosthetic to the patients knee.[11, 13] It is projected that over a million
primary total knee replacements (TKR) will occur by 2030 in the United States.[63] While bone
cement has been shown to last up to 15 years within a patient, it lacks in osteoconduction and
osteoinduction, thus cell ingrowth and bone regeneration does not occur.[64] Many state-of-theart biomaterials are shifting to a composite augment utilizing calcium phosphate additives to
increase the osteogenic properties of the biomaterial.[65] Another major constraint of bone
cement is the working time of the material, which greatly constrains clinicians during tissue
preparation. According to Lidgren et al., for Palacos® bone cement that was thoroughly mixed
by hand at 21°C, it took about 4.27 minutes to harden enough to mold, 5.19 minutes of moldable
or handling time, and 10.18 minutes to reach a fully set polymer.[8] Unfortunately, if the
physician and operating room staff are unable to prepare the bone cement correctly or if the mold
does not fit properly, the entire process must be restarted creating waste, inefficiency, and
compromises quality.
After the literature review of the different types of materials recently discovered for
support of knee prosthetics, a potential solution to the working lifetime issue might be found by
using thermal frontal polymerization (TFP) to form a bone augment. TFP proceeds via a
thermally-induced free-radical polymerization mechanism. The polymerization is initiated by
the decomposition and radical formation of benzoyl peroxide and follows the mechanism in
Scheme 1.
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Figure 3.1 – Thiol-ene free-radical chain growth polymerization mechanism.

The thiyl radical only forms in the reactions with trimethylolpropane tris-(3-mercaptopropionate)
(TMPTMP). The pores within the augment form as a result from the release of CO2 as a byproduct from using the peroxide initiator. This reaction has been demonstrated in water and
other organic solvents.[66, 67] It has also been shown that any gases or water dissolved within
the monomers can be volatilized during the reaction and lead to bubble formation.[66]
A study by Garber et al. on a novel bone construct displayed high biocompatibility using
pentaerythritol-co-trimethylolpropane tris-(3-mercaptopropionate) formed by a copolymerization
with an amine-catalyzed Michael addition mechanism.[68]

This study utilized a foaming

mechanism to generate a porous scaffold and conducted an in vivo model to test the
biocompatibility and osteogenic properties.[69] The osteogenic results have led to the potential
of utilizing these acrylate and thiol monomers, however due to their lack of cure-on demand
these will be used under the free-radical frontal polymerization mechanism, to result in a
biocompatible scaffold.
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Thermal frontal polymerization utilizes a local free-radical reaction that propagates in a
wave like pattern. This front travels due to the coupling of the thermal diffusion and the
Arrhenious dependence of the reaction rate of an exothermic polymerization. The front travels at
a front velocity dependent on the initiator concentration, temperature, pressure, and the type of
monomer.[70]
An extract study was done to test cytotoxicity, and then front velocity measurements and
temperature profiles were made. Finally, a pot life study, mechanical property analysis, mass
loss analysis, and imaging of the augments were done. Utilizing these monomers via a TFP
mechanism instead of the Michael addition mechanism, bone augment synthesis can be
conducted with an extended working time and at a rapid reaction rate. This cure-on demand
capability empowers the physician to fully shape and mold the monomer form before setting the
polymer. This reaction occurs in a short time period and leads to a biologically friendly augment
that supports and promotes cell growth. This study uses NIH 3T3 cells for an in vitro cytotoxic
evaluation.[71] One application of this material could be as a substitute for currently used bone
cement in total knee replacement.
3.3 Materials and Methods
3.3.1 Materials
Materials for augment synthesis were used as obtained from Sigma Aldrich:
trimethylolpropane tris(3-mercaptopropionate) (TMPTMP), Luperox A98 - benzoyl peroxide
(BPO), hydroxyapatite (HA), and from Alfa Aesar: pentaerythritol triacrylate (PETA).
Augment Synthesis:
Four different composites were synthesized at different ratios of acrylate to thiol. Chen et
al.’s procedure to find the lowest concentration of benzoyl peroxide was conducted, and all are
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synthesized with 0.5% (w/w) BPO (data not shown).[72]

Per Garber et al.’s display of

bioactivity, all augments were made with 20% (w/w) HA.[68] The ratio of acrylate to thiol is as
follows in Table 3.1:
Table 3.1 – Ratios of PETA to TMPTMP per construct by mass.
Sample Name Percent PETA by mass Percent TMPTMP by mass
100
0
Acrylate only
90
10
9 to 1
80
20
4 to 1
66
33
2 to 1

Ratios of PETA to TMPTMP with greater amounts of TMPTMP were tested, but were unable to
polymerize via thermal frontal polymerization. From henceforth all composites will be referred
to by their ratio of PETA to TMPTMP.
Monomers of PETA and BPO were mixed for 24 hours prior to addition of TMPTMP
and HA. All augments containing the TMPTMP and HA were mixed in the same order and
duration using a rotor for 1 minute for each monomer. Fronts were initiated with a commercial
soldering iron or a hot plate depending on the mold (See Supplemental Information).
3.3.2 Cell Culture
NIH 3T3 mouse fibroblast from passages 30 to 55 were cultured in Dulbecco’s Modified
Eagle Medium (DMEM) with 10% fetal bovine serum in 25 cm2 tissue culture flasks. All cells
were incubated at 37°C and 5% CO2. The media was changed in each flask every 3 days and
passaged at 80% confluence.
3.3.3 Extract Cytotoxicity
A 96 well tissue culture plate was seeded with 1 x 105 3T3 mouse fibroblast cells and
incubated at 37°C and 5% CO2 for 24 hours. Three replicates of 200 mg +/- 2.3 mg augment
structures were soaked in 5 mL of DMEM with 10% fetal bovine serum and placed on a rocker
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while being incubated at 37°C and 5% CO2 for 7 days. The extract solution was then filtered
through a 0.22 µm pore size filter, and 150 µL per well was placed into a 96 well tissue culture
plate that was seeded with 3T3 mouse fibroblast cells. Samples were incubated at 37°C and 5%
CO2 for 24 hours and cellular viability was analyzed using the Alamar Blue assay. The dead
control was conducted by adding 100% ethanol to wells with cells for 4 hours prior to staining.
This assay called for 10 µL of Alamar Blue reagent to be added to 100 µL of culture medium per
well and incubated at 37°C and 5% CO2 for 4 hours. The fluorescence was measured at an
excitation wavelength of 535 nm and an emission wavelength of 595 nm using a plate reader.
3.3.4 Front Velocity and Temperature Profile
Monomers of each sample were placed in a metal mold, measuring 0.7 cm x 1.3 cm x
10.2 cm. A commercial soldering iron was used to initiate thermal frontal polymerization. The
front velocity was calculated by capturing the reaction via video and determining the time
required for the reaction front to travel 1.27 cm in three different portions of the total length of
the mold. The temperature profile was captured using a type T thermocouple and collected by a
USB TC-08 Thermocouple Data Logger.[67] Polymerization was performed in triplicate and
deemed successful if a self-sustaining front propagated.[73]
3.3.5 Pot Life Study
Monomers of each augment type were mixed and left at room temperature. The time until
bulk polymerization occurred was determined in triplicate.
3.3.6 Mechanical Testing
All samples were compressed at 2.5 mm per minute using an Instron (Instron Model
5696, Canton, MA) until a yield point or 10% deformation was reached. The samples were
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cylindrical with 6 mm in diameter and 12 mm in height. Sample testing was a modified version
of Kim et al.’s protocol.[14]
3.3.7 Mass Retention Test
Three replicates of each augment structure were soaked in DMEM with 10% fetal bovine
serum and placed on a rocker while being incubated at 37°C and 5% CO2 for 7 days. Composite
samples were trypsinized (0.25% trypsin, 1X EDTA) for 10 minutes then rinsed three times in
phosphate buffered saline (-Ca, -Mg) and freeze dried. Each sample was normalized to its’
initial mass prior to media exposure.[68]
3.3.8 Scanning Electron Microscope Analysis
The cross-sectional view was observed by scanning electron microscopy. The cylindrical
augment synthesized for mechanical testing was cut to a 3 mm height. A conductive platinum
coating was applied using EMS550X sputter coater for two-2 minute coatings.
3.3.9 Micro-Computerized Tomography Analysis
Each cylindrical structure from mechanical testing was placed into the micro-CT and
imaged with a SkyScan Model 1074 microtomography scanner, the x-ray source voltage was 40
kV, the source current was 1000 microamps (uA), and the exposure time ranged from
approximately 300 msec to 600 msec. The scanner had a detector with 37 m pixel size, the xray source was 3 m, and the effective (reconstructed) spatial resolution was about 80 m fullwidth-at-half-maximum (FWHM). Scaffold porosity was calculated using the Image Processing
toolbox in MATLAB v7.12 (MathWorks, Natick, MA).
3.3.10 Statistical Analysis
All results were expressed as a mean ± percent error. Data were analyzed with a two way
t-test. For all comparisons, a p-value < 0.05 was determined significant.
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3.4 Results
3.4.1 Effect of Acrylate and Thiol Concentrations
In comparing the reaction properties of the different ratios of acrylate to thiol in Table
3.1, as the amount of thiol was increased, the front velocity decreased from 0.45 cm/sec for the
Acrylate only down to 0.12 cm/sec for the 2:1 acrylate to thiol augment, as seen in Figure 3.1.
While the front was retarded, the maximum temperature inversely correlated with thiol content
with temperatures reducing from 200°C to 124°C.

Figure 3.2 Front position versus time for all acrylate to thiol ratios with 0.5% (w/w) benzoyl
peroxide and 20% (w/w) hydroxyapatite.

The temperature for the Acrylate only augment was 200°C +/- 10°C, 9:1 acrylate to thiol
augment was 180 +/- 10°C, the 4:1 acrylate to thiol augment was 160°C +/- 10°C, and the 2:1
acrylate to thiol augment was 124°C +/- 4°C. The front velocity of the Acrylate only augment
took 6.83 +/- 0.33 minutes to react and cool to 40°C, while the 9:1 acrylate to thiol reached 40°C
in 8.10 +/- 0.38 minutes. Similar to the decreasing trend of maximum temperature, the total time
decreased from the 9:1 to the 2:1 acrylate to thiol augment with the 4:1 acrylate to thiol augment
at 6.38 +/- 0.88 minutes and the 2:1 augment at 5.17 +/- 0.53 minutes, shown in Figure 3.2.
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Figure 3.3 Temperature profile of Acrylate only, 9 to 1, 4 to 1, and 2 to 1 ratio of acrylate to
thiol. The thermocouple was located at the center of a 1.3 cm x 0.7 cm x 10.3 cm mold.
3.4.2 Effect of Acrylate and Thiol Concentrations on Cytocompatibility
Although the reaction properties mostly trended from Acrylate only to the 2:1 acrylate to
thiol augment, the biological properties displayed a trend toward the augments with the middle
ratios of acrylate to thiol, as shown in Figure 3.3. High biological compatibility from the
extracts of the augments was only displayed by the 9:1 and 4:1 acrylate to thiol augments. These
augments displayed above 100 percent, normalized to the live control, of cell viability in the
extract of these augments.
3.4.3 Pot Life Study
In Figure 3.4, as the amount of thiol was increased there was a decrease in the stability of
the system at room temperature before bulk polymerization occurred.

The Acrylate only

augment lasted greater than 24 hours, while even the 9:1 augment only lasted 2 hours. The 4:1
augment and the 2:1 acrylate to thiol augment had 1 and 0.75 hour pot lives, respectively.

27

Figure 3.4 – Relative metabolic activity of 3T3 mouse fibroblast cells in acrylate or thiol-acrylate
extractives as quantified via an Alamar Blue fluorescent assay. Asterisk indicates sample is
significantly different from the dead control.

Figure 3.5 – Pot life study of lifetime of the reaction once all monomers are mixed. **All
samples were significant from each other.

3.4.4 Mechanical Strength
With the addition of thiol, the ultimate compressive strength was observed to increase as
shown in Figure 3.5 from as low as 0.87 MPa for the Acrylate only to 3.65 MPa for the 4:1
acrylate to thiol augment.

The mechanical strength plateaued at the 4:1 acrylate to thiol

augment, thus the 2:1 acrylate to thiol augment withstood the same amount of compressive
forces.
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Figure 3.6 – Compressive strength tested at a rate of 2.5 mm/min until the yield point was
reached or at 10% deformation. *Indicates significance of p < 0.05.
The Young’s modulus displays a similar trend as the ultimate compressive strength with
the Acrylate only being the stiffest at 6.25 MPa and leveling off at 30.7 MPa for the 4:1 acrylate
to thiol augment in Figure 3.6.

Figure 3.7 – Young’s Modulus tested using an Instron at a rate of 2.5 mm/min until the yield
point was reached or at 10% deformation. *Indicates significance of p < 0.05.
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3.4.5 Mass Retention Study
Each formulation experienced a small decrease in mass as illustrated in Figure 3.7, except
for the 4:1 acrylate to thiol augment. The mass retained was within a range of 1.1% for the
Acrylate only, 9:1, and 2:1 acrylate-to-thiol formulation. The 4:1 formulation had a larger range,
and lower mass retention at 93.6% retained.

Figure 3.8 – Mass retained after 7 days in tissue culture media at 37°C. *Indicates significance of
p < 0.05.
3.4.6 Porosity and Imaging
Total porosity inversely correlated with increasing thiol concentration, except for the 4:1
acrylate to thiol composition. All samples showed less than 23% porosity with the 2:1 acrylate
to thiol formulation having the lowest porosity at 5.9%. The 4:1 acrylate to thiol augment did
not hold this trend; with higher porosity than the Acrylate only augment at 23%, as shown in
Figure 3.9.
The SEM image in Figure 3.9, of the 4:1 acrylate to thiol augment, shows a crosssectional image of the morphology. The average pore diameters of the macropores were 120 µm
with micropores between 1 µm and 10 µm.
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Figure 3.9 – Porosity of augments with varying ratios of acrylate to thiol. All ratios have 0.5%
(w/w) benzyol peroxide and 20% (w/w) hydroxyapatite. . **All samples were significant from
each other.

Figure 3.10 – Scanning electron microscopy of: a) Acrylate only, b) 9:1 ratio of acrylate to thiol,
c) 4:1 ratio of acrylate to thiol, d) 2 to 1 ratio of acrylate to thiol displaying consistent porosity.

The 4:1 acrylate to thiol augment cross-sectional view was also examined via micro-CT
imaging as shown in Figure 3.10 a) and reconstructed imaging to display the outer structure in
the 3D image shown in Figure 3.11. Figure 3.10 portrays the internal porosity and some slight
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elongation of the pores from the bottom left to the top right of image a) and can be compared to
the 9:1 augment in image b).

Figure 3.11 - micro-CT cross-sectional slice of: a) Acrylate only, b) 9:1 ratio of acrylate to thiol,
c) 4:1 ratio of acrylate to thiol, d) 2 to 1 ratio of acrylate to thiol. Analyzed via MATLAB.
Augment cylinders are 6 mm in diameter and 12 mm in height. Scale bar is 6 mm.

Figure 3.12 - micro-CT 3D image of: a) Acrylate only, b) 9:1 ratio of acrylate to thiol, c) 4:1
ratio of acrylate to thiol, d) 2 to 1 ratio of acrylate to thiol. Augment cylinder is 6 mm in diameter
and 12 mm in height. Scale bar is 6 mm.
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3.5 Discussion
Thermal frontal polymerization works by the feedback between the heat released by the
polymerization and the Arrhenius dependence of the polymerization rate on temperature. Most
of the temperature dependence is through the decomposition of the initiator. Benzoyl peroxide
was chosen as an initiator due to its prevalence in bone cement and other biomaterials.[74, 75]
The self-propagating front can be locally initiated and propagate from a heat source to cure the
entire polymer. The initiation temperature is dependent on the geometry of the monomer, the
materials it is in contact with, and the external environment (i.e. room temperature). These
factors also affect the reaction rate, and so the temperature and reaction rate will depend on the
application.[70] By using a fine tipped heat source the physician only needs access to a small
portion of the monomer and would still be able to cure an area that is covered or not easily
reachable.
This study was conducted to determine material’s structure as a function of the thiol
concentration. Three ratios of acrylate to thiol were synthesized, 9:1, 4:1, and 2:1 by weight, and
one composition without thiol. Ratios of 1:1 and 4:3 by weight of acrylate to thiol did not
frontally polymerize due to the high concentration of thiol.[76]
Working with the three ratios of acrylate to thiol and the Acrylate only material, the
results display the high extract cell viability of the 9:1 and 4:1 augments. The cell death in the
Acrylate only augment is believed to have occurred due to the leeching of excess acrylate
monomer that decomposes into acrylic acid.[77]

The build-up of excess monomer in the

Acrylate only augment is attributed to the low monomer conversion, especially at the surface of
the augment.

While the excess acrylate monomer caused cell death in the Acrylate only

augment, it is hypothesized that hydrolyzed thiol monomers, and/or a change in pH may have
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caused the cell death observed in the 2:1 ratio samples.[78] Thiyl radicals are known to onset the
mechanism for cell damage by thiols.[79, 80] It is also possible that, due to the lower front
temperature, there were unreacted thiols that diffused out of the scaffold and were able to follow
a similar pathway to the thiyl radical, disrupting the cell membrane, and lysing the cells. It is
presupposed that this release of thiol monomer over the 7 days occurred in all the of the
augments with thiol, but the concentration released within the 2:1 acrylate to thiol augment was
high enough to lead to cell lysis.
For use as a surgical augment, the temperature change caused by the reaction must be
considered. The trends of the augments exhibit the increase in temperature with a decrease in
thiol concentration. This is due to lower enthalpy of the copolymerization of a thiol with an
acrylate compared to that of the homopolymerization of acrylate. With fewer acrylate-acrylate
bonds formed, the temperature decreased in the 9:1, 4:1, and 2:1 augments. When comparing
these augments to bone cement’s temperature range, from 70°C to 120°C during polymerization
the 4:1 and the 2:1 acrylate to thiol augments are the two that are closest to and within the bone
cement range. The bone cement’s duration at an elevated temperature is longer than that of the
4:1 acrylate to thiol augment.[81] The quick heating and rapid cooling could limit the amount of
tissue damaged at the surgery site. The time for augments to react and cool to 40 °C for the 4:1
augment was less than that of bone cement, for bone cements reaction time alone is greater than
the duration to heat and cool the augments. Thus, this fast reaction is advantageous for the
physician’s total working time and the amount of time the tissue is exposed to high, potentially
damaging, temperatures.
As shown by Viner et al., as the thiol concentration is increased, bulk polymerization
initiated by a redox reaction between the thiol and peroxide becomes favorable. Also, the thiol
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acts by decreasing the oxygen inhibition. The greater the concentration of thiol the greater is the
decrease in bulk polymerization pot life.[73] This trend of decreased pot life was shown from
the 9:1 to the 2:1 acrylate to thiol augments.
The mechanical properties are shown to increase as the thiol concentration is increased,
correlating indirectly with the porosity study. As the thiol concentration was increased from the
9:1 to the 2:1 acrylate to thiol formulation, the maximum temperature decreased, likely resulting
in less expansion. The decrease in porosity ultimately led to an increase in the mechanical
strength of the samples with lower acrylate content.

Due to the porosity, the frontally

polymerized augment is about one twentieth of the strength of commercially available bone
cement.
The large distribution in mass retention and porosity for the 4:1 sample is hypothesized to
be a result of the carbon dioxide released from the scaffold. In future studies, adjusting the
porosity can be achieved by a change in the concentration of BPO, initiator.[70, 82] This could
decrease the amount of gas released, providing a narrower distribution of mass retention and
porosity, and result in consistent porosity similar to what is observed within the 9:1 and 2:1
acrylate to thiol augments.[66]
Cordell et al. has shown the importance of micropores for initial cell adhesion and the
importance of macropores between 100 µm to 150 µm pores for cell growth and mineral
formation.[83]

With Cordell et al.’s augments having both micropores and macropores,

adequate structure for adhesion, nutrient and waste flow, could lead to cell ingrowth post
implantation.
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3.6 Conclusion
Utilizing thermal frontal polymerization provides an opportunity for physicians to utilize an
alternative to traditional bone cement with an extended working time but a “cure-on demand”
capability. This study explored the effect of different ratios of frontally polymerized acrylate to
thiol and concluded that the 4:1 ratio of acrylate to thiol augment displayed the optimal
cytocompatibility, mechanical strength, and porosity when compared to the Acrylate only, 9:1
and 2:1 acrylate to thiol augments. Based in these results the 4:1 augment may prove useful as a
substitution for bone cement in orthopedic repair procedures.
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4. SUMMARY, CONCLUSIONS, AND RECOMMENDATIONS
4.1 Summary
Knee arthorplasties were forever changed when Dr. Charnley first used PMMA as a
spacer between the metal prosthetic and native bone. PMMA bone cement has been widely
characterized in literature, with many modifications, and several unique formulas are used
commercially today. Through this study of a triacrylate-co-trithiol by polymerization via
free-radical frontal polymerization, a construct was synthesized with potential for use as a
substitute for bone cement. This augment was made to address the physician’s concerns of
short molding time and to gain control of initiating polymerization. Through use of thermal
frontal polymerization, both these concerns were addressed.
This augment provides a similar system to the currently used bone cement where in
PMMA bone cement powder and the liquid initiator, are mixed. However the PMMA bone
cement commences polymerization once mixed, while the construct developed in this study
must be heat catalyzed. These results in increased working time for the physician to shape
and mold the monomer mixture. The temperature trigger provides a form of control for the
physician and will aid in decreasing the amount of errors, removal of the erroneous cement,
and re-molding of the cement. Also, due to the reaction between the thiol and BPO, any
monomer not reacted will polymerization in a bulk manner.
To explore the potential of this technique an in vitro study was conducted to test the
cytocompatibility, mechanical properties, and the curing time as a function of the ratio of
acrylate to thiol monomers by weight percent. The acrylate only, 9 to 1 acrylate to thiol, 4 to
1 acrylate to thiol, and 2 to 1 acrylate to thiol polymers underwent an extract metabolic assay,
compression testing, and imaged via micro-computed tomography for porosity analysis.
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4.2 Conclusions
The results of this study indicate that the 4 to 1 acrylate to thiol bone augment had a curing
temperature most similar to PMMA bone cement while having the highest cytocompatibility,
compressive strength, and porosity of the augments tested. This provided a platform for use of
frontal polymerization and a “cure-on-demand” system as a synthetic material for a biological
application. With innate porosity, due to the production of gas during polymerization, the TFP
mechanism is reliable for allotting space for cell ingrowth and nutrient or waste flow for cells.
The maximum temperature during polymerization can be tuned with the addition of fillers within
the monomers, and the total reaction time is shorter than that of PMMA bone cement.
Through in vitro testing, the 9 to 1 and 4 to 1 acrylate to thiol augments has shown positive
results from their extract cytotoxicity assays with mouse derived fibroblast cells. This provides
more insight to the balance and proper ratio between acrylate and thiol monomers within the
polymer to reach a non-toxic level.
The mechanical properties of the augment initially increased with incorporation of thiol
monomer then plateaued at higher thiol concentrations. This correlated with the porosity of the
each of the monomers and was verified via SEM and micro-CT imaging.
4.3 Recommendations
1. Adjusting and expanding the additions of other bioactive molecules. This may lead to
better osseointegration and osteoinduction.
2. By adjusting the hydroxyapatite (filler) weight percentage, the maximum temperature can
be decreased further below the curing temperature of state-of-the-art bone cements..
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3. While the gas produced induces the necessary porosity needed, measuring expansion of
the polymer as a function of porosity could aid in fine-tuning the porosity and in
optimizing the clinical application of this technology.
4. Tensile, flexure, and fatigue testing should be done to better understand the constructs
mechanical limitations particularly in physiologically relevant conditions.
5. An in vivo study within small animals (i.e. murine) could be conducted to better
understand the biocompatibility, mechanical strength, and osteogenic potential of the
scaffold.
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